Tag Archives: acute

Melatonin — A Standard of Treatment Adjunct for Acute Infections?

This article was previously published October 19, 2020, and has been updated with new information. According to a June 2020 research paper,1 melatonin2,3 may be an important adjunct to COVID-19 treatment. Incidentally, while not emphasized, melatonin is an optional addition to the highly effective MATH+ protocol promoted by the Front Line COVID-19 Critical Care Working… Read More »

FDA Approves Rylaze for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

FDA Approves Rylaze for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma DUBLIN, June 30, 2021 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute… Read More »

Retail scripts of vaccines, acute drugs decline sharply amid COVID-19 pandemic

It’s understandable that retail prescriptions of drugs have declined since COVID-19 hit the U.S., as patients refrain from visiting physicians. But still, some drugs are suffering terribly, while others appear to be holding steady. Broadly speaking, total prescriptions for drugs for acute use have plummeted by 28% since February, Bernstein analysts noted after going through… Read More »

Statement on National Academies of Sciences, Engineering, and Medicine report on framing opioid prescribing guidelines for acute pain – FDA.gov

For Immediate Release: December 19, 2019 Statement From: Statement Author Leadership Role Director – Center for Drug Evaluation and Research Janet Woodcock M.D. In August 2018, the U.S. Food and Drug Administration contracted the National Academies of Sciences, Engineering, and Medicine (NASEM) to help advance the development of evidence-based guidelines for opioid analgesic prescribing for… Read More »